Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 11/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 10/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 7/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 7/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 1.00 |
| ▸ | HTR6 | P50406 | 7/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | HTR1F | P30939 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2511706 | 1.00 | HDAC6 (1.00) | HDAC6HDAC1HDAC2HDAC8HDAC3 | |
| SCHEMBL18649848 | 1.00 | HDAC6 (1.00) | HDAC6HDAC1HDAC2HDAC8HDAC3 | |
| SCHEMBL18649847 | 0.86 | HDAC1 (0.76) | HDAC6HDAC1HDAC2HDAC8HDAC3 | |
| SCHEMBL2512626 | 0.86 | HDAC1 (0.76) | HDAC6HDAC1HDAC2HDAC8HDAC3 | |
| SCHEMBL2512629 | 0.86 | HDAC1 (0.76) | HDAC6HDAC1HDAC2HDAC8HDAC3 | |
| SCHEMBL8354467 | 0.82 | HDAC3 (0.70) | HDAC6HDAC1HDAC2HDAC8HDAC3 | |
| SCHEMBL2510571 | 0.81 | HDAC8 (0.68) | HDAC6HDAC1HDAC2HDAC8HDAC3 | |
| SCHEMBL2511481 | 0.81 | HDAC8 (0.68) | HDAC6HDAC1HDAC2HDAC8HDAC3 | |
| SCHEMBL14070488 | 0.80 | HDAC3 (0.66) | HDAC6HDAC1HDAC2HDAC8HDAC3 | |
| SCHEMBL7443418 | 0.80 | HDAC3 (0.66) | HDAC6HDAC1HDAC2HDAC8HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552887-B1 | INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS | UNIV TAIPEI MEDICAL (TW) | 2018-10-24 | — | — | EP | claimed |
| EP-2552887-B1 | INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS | UNIV TAIPEI MEDICAL (TW) | 2018-10-24 | — | — | EP | disclosed |
| EP-2763673-B1 | USE OF INDOLYL HYDROXAMATES FOR TREATING HEART FAILURE OR NEURONAL INJURY | UNIV TAIPEI MEDICAL (TW) | 2018-08-01 | — | — | EP | disclosed |
| US-9598364-B2 | Indolyl or indolinyl hydroxamate compounds | TAIPEI MEDICAL UNIVERSITY (TW) | 2017-03-21 | — | — | US | disclosed |
| US-9598364-B2 | Indolyl or indolinyl hydroxamate compounds | TAIPEI MEDICAL UNIVERSITY (TW) | 2017-03-21 | — | — | US | disclosed |
| US-20160303079-A1 | USE OF INDOLYL AND IDOLINYL HYDROXAMATES FOR TREATING NEURODEGENERATIVE DISORDERS OR COGNITIVE DECICITS | TAIPEI MEDICAL UNIVERSITY (TW) | 2016-10-20 | — | — | US | disclosed |
| US-9296692-B2 | Use of indolyl and indolinyl hydroxamates for treating heart failure of neuronal injury | TAIPEI MEDICAL UNIVERSITY (TW) | 2016-03-29 | — | — | US | disclosed |
| WO-2015077685-A1 | USE OF INDOLYL AND IDOLINYL HYDROXAMATES FOR TREATING NEURODEGENERATIVE DISORDERS OR COGNITIVE DEFICITS | DCB-USA LLC (US) | 2015-05-28 | — | — | WO | disclosed |
| US-20150065552-A1 | Use of Indolyl and Indolinyl Hydroxamates for Treating Heart Failure of Neuronal Injury | TAIPEI MEDICAL UNIVERSITY (TW) | 2015-03-05 | — | — | US | disclosed |
| US-20140364477-A1 | INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS | TAIPEI MEDICAL UNIVERSITY (TW) | 2014-12-11 | — | — | US | disclosed |
| US-20140364477-A1 | INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS | TAIPEI MEDICAL UNIVERSITY (TW) | 2014-12-11 | — | — | US | disclosed |
| US-8846748-B2 | Indolyl or indolinyl hydroxamate compounds | TAIPEI MEDICAL UNIVERSITY (TW) | 2014-09-30 | — | — | US | disclosed |
| US-8846748-B2 | Indolyl or indolinyl hydroxamate compounds | TAIPEI MEDICAL UNIVERSITY (TW) | 2014-09-30 | — | — | US | disclosed |
| WO-2013040520-A1 | USE OF INDOLYL AND INDOLINYL HYDROXAMATES FOR TREATING HEART FAILURE OF NEURONAL INJURY | TAIPEI MEDICAL UNIVERSITY (TW) | 2013-03-21 | — | — | WO | disclosed |
| EP-2552887-A2 | INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS | Taipei Medical University (TW) | 2013-02-06 | — | — | EP | disclosed |
| WO-2011126821-A2 | INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS | TAIPEI MEDICAL UNIVERSITY (TW) | 2011-10-13 | — | — | WO | disclosed |
| US-20110245315-A1 | INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS | TAIPEI MEDICAL UNIVERSITY (TW) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303079-A1 | USE OF INDOLYL AND IDOLINYL HYDROXAMATES FOR TREATING NEURODEGENERATIVE DISORDERS OR COGNITIVE DECICITS | IDO1, IDO2, HTT | HDAC6 103/4885HDAC1 752/4885HDAC2 345/4885 |
| US-20150065552-A1 | Use of Indolyl and Indolinyl Hydroxamates for Treating Heart Failure of Neuronal Injury | TNNI3, NLN, TNNT2 | HDAC6 29/4885HDAC1 32/4885HDAC2 42/4885 |
| US-20110245315-A1 | INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS | IDH3A, IDH2, IDH3B | HDAC6 35/4885HDAC1 8/4885HDAC2 20/4885 |
| US-20140364477-A1 | INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS | IDH3A, IDH2, IDH3B | HDAC6 35/4885HDAC1 8/4885HDAC2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.